Hepatitis C virus (HCV) is a leading cause of liver disease worldwide. The development of much needed specific antiviral therapies and an effective vaccine has been hampered by the lack of a convenient small animal model. The determinants restricting HCV tropism to human and chimpanzee hosts are unknown. Replication of the viral RNA has been demonstrated in mouse cells 1,2 , but these cells are not infectable with either lentiviral particles bearing HCV glycoproteins (HCVpp) 3 or HCV produced in cell culture (HCVcc) (A.P., M.E. and C.M.R., unpublished observations), suggesting that there is a block at the level of entry. Here we show, using an iterative complementary DNA library screening approach, that human occludin (OCLN) is an essential HCV cell entry factor that is able to render murine cells infectable with HCVpp. Similarly, OCLN is required for the HCV-susceptibility of human cells, because its overexpression in uninfectable cells specifically enhanced HCVpp uptake, whereas its silencing in permissive cells impaired both HCVpp and HCVcc infection. In addition to OCLN, HCVpp infection of murine cells required expression of the previously identified HCV entry factors CD81 (ref. 4), scavenger receptor class B type I (SR-BI, also known as SCARB1) 5 and claudin-1 (CLDN1) 6 . Although the mouse versions of SR-BI and CLDN1 function at least as well as the human proteins in promoting HCV entry, both OCLN and CD81 must be of human origin to allow efficient infection. The species-specific determinants of OCLN were mapped to its second extracellular loop. The identification of OCLN as a new HCV entry factor further highlights the importance of the tight junction complex in the viral entry process, and provides an important advance towards efforts to develop small animal models for HCV.
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HCV virions, lipid-enveloped nucleocapsids bearing the viral glycoproteins E1 and E2, seem to enter a host cell in a highly coordinated process involving components of the virus particle and numerous cellular factors 7 . From the long list of putative HCV entry factors, strong evidence supports specific roles for the tetraspanin CD81 (ref. 4 ), SR-BI 5 and the tight junction protein CLDN1 (ref. 6 ). This list appears incomplete, however, as numerous human cell lines and all non-primate cell lines are resistant to HCV entry even when all three human factors are overexpressed (refs 3, 6 and data not shown).
To identify additional factors that can render non-human cells susceptible to HCV entry, we performed a cyclic retrovirus-based repackaging screen of a cDNA library derived from the highly HCV-permissive human hepatocarcinoma Huh-7.5 cell line 8 . We screened for genes that rendered a non-permissive mouse embryonic fibroblast cell line, NIH3T3, infectable with HCVpp, defective lentiviral particles that display the HCV glycoproteins and measure only viral entry [9] [10] [11] ( Supplementary Fig. 1a and Supplementary Methods).
To maximize the likelihood of identifying a new component that would permit HCV entry into non-human cells, we used an NIH3T3 subclone overexpressing human CD81, SR-BI and CLDN1. This screen identified human OCLN as a potential HCV entry factor. OCLN is a four transmembrane domain protein present in the tight junction complex of polarized epithelial cells, where it probably functions to regulate paracellular permeability and cell adhesion 12, 13 . Expression of human CD81, SR-BI, CLDN1 and OCLN in NIH3T3 cells enhanced HCVpp infectivity by approximately 120-fold ( Fig. 1c and Supplementary Fig. 1c ).
To confirm that OCLN is required for HCV entry, we examined the relationship between its expression and HCV susceptibility in a variety of human cell lines. Naturally HCV-permissive human hepatoma cell lines (Huh-7.5 and Hep3B) or those previously shown to lack other entry factors (hepatocellular carcinoma HepG2 and embryonic kidney 293T cells) were found to express readily detectable levels of endogenous OCLN ( Supplementary Fig. 1d ). In these cells, further overexpression of OCLN did not enhance susceptibility to HCVpp (Fig. 1a ). Silencing of OCLN, however, inhibited HCVpp infection of Hep3B cells (Fig. 2f ), and both HCVpp and HCVcc infection of Huh-7.5 cells ( Fig. 2e and g, respectively), indicating that OCLN is essential for HCV infection of naturally permissive cells. This inhibition was HCV-specific, as infection with pseudoparticles bearing the vesicular stomatitis virus glycoprotein (VSVGpp) was not affected (values in Fig. 2e -f are corrected for VSVGpp infectivity). Notably, OCLN knockdown resulted in incomplete inhibition of HCVpp infection for both cell lines. This is probably due to incomplete silencing or stable reservoirs of the protein that remained to contribute some entry functions. In contrast, the naturally HCVresistant renal carcinoma cell line 786-O expresses high levels of the major HCV entry factors CD81, SR-BI and CLDN1, but approximately 17-fold less OCLN than Huh-7.5 cells ( Supplementary Fig.  1d ). OCLN overexpression in 786-O cells specifically enhanced HCVpp infection by more than 88-fold ( Fig. 1a ). Furthermore, this OCLN-dependence of HCVpp infection was observed across a panel of diverse HCV genotypes ( Fig. 1b ). Another HCVpp-resistant cell line-the HeLa cell-derived cervical carcinoma line TZM-was found to lack both endogenous CLDN1 and OCLN (more than 100-and 25-fold less messenger RNA than Huh-7.5 cells, respectively; Supplementary Fig. 1d ). Overexpression of these factors together increased HCVpp infectivity of TZM cells by 450-fold ( Fig. 1a ). These results indicate that OCLN is an essential HCV entry factor.
To examine HCV entry requirements in non-human cells further, we transduced murine NIH3T3 cells with all combinations of one, two, three or all four human CD81, SR-BI, CLDN1 and OCLN proteins. Fig. 1c ). Permissiveness to VSVGpp was not affected by expression of the human proteins. Attempts to infect these murine cells with HCVcc were unsuccessful, probably as a result of inefficient viral RNA replication in these cells, as previously documented 1,2 . It is interesting that different murine cell lines showed varying degrees of HCVpp entry permissiveness after transduction with all four factors. HCV entry factor levels or cell determinants affecting lentivirus reporter expression do not seem to explain the observed differences (because the data were normalized to VSVGpp). Instead, these cell type specific differences may reflect real biological variability in other cellular machinery involved in HCV entry.
To investigate which of the four entry factors are responsible for HCV species-specific tropism, we performed further experiments in Chinese hamster ovary (CHO) cells, which express low endogenous levels of SR-BI, CLDN1 and OCLN ( Supplementary Fig. 4b ). In CHO cells overexpression of all four human factors specifically enhanced Hep3B Hep3B (right) cells transfected with irrelevant (white), CD81-specific (checkered) or OCLN-specific (black) short interfering RNA (siRNA) pools were stained with CD81 (a and b) and OCLN (c and d) antibodies. Expression was analysed by flow cytometry; the difference between specific and isotype control (IgG ctrl) staining is shown. Concurrently, siRNAtreated cells were challenged with HCVpp (e and f) and HCVcc (g). HCVpp infectivity was calculated as described in methods; HCVcc infection was quantified by the difference between viral protein (NS5A) and isotype control staining. All samples are normalized to irrelevant-siRNA treatment. dMFI, difference in mean fluorescence intensity. Means and s.d. of at least triplicate experiments are shown.
HCVpp infection by 60-to 336-fold ( Fig. 3b and Supplementary Fig.  4a ). Although omission of CD81, CLDN1 or OCLN abolished HCVpp entry, a low level of endogenous SR-BI in CHO cells provided some HCVpp entry function when the other three factors were transduced ( Supplementary Fig. 4a ). However, because the overexpression of SR-BI further enhanced entry by threefold in the context of the other human proteins ( Supplementary Fig. 4a ), we still considered CHO cells to be a suitable environment in which to study the species-specific functions of each factor. To do so, we transduced CHO cells to express every combination of human and mouse CD81, SR-BI, CLDN1 and OCLN. In all combinations, mouse SR-BI functioned equivalently to that of human origin (Fig. 3b ). This shows for the first time that mouse and human SR-BI are equally capable of mediating HCV uptake. In CHO cells, mouse CLDN1 seems to be slightly more functional for HCVpp entry than the human protein (Fig. 3b ). This is in agreement with a slight preference observed when either of these CLDN1 proteins, which are 90% identical, were expressed in human 293T cells 6 . These observations were confirmed by transducing mouse NIH3T3 cells with human CD81 and OCLN and all permutations of mouse and human SR-BI and CLDN1 (Fig. 3c) . Although SR-BI showed little to no species specificity, NIH3T3 cells expressing mouse CLDN1, in addition to the other three entry factors, were slightly more permissive to HCVpp than the same cells expressing human CLDN1. The determinants for this CLDN1 preference have not yet been examined, but it remains clear that CLDN1 does not contribute to the restriction to HCVpp entry in mouse cells. Notably none of the mouse cells examined above express sufficiently high levels of either murine SR-BI or CLDN1 ( Supplementary Fig. 4d, e ), thus explaining their dependence on transduction of these proteins for HCVpp permissivity. In contrast, CD81 and OCLN showed human-specific HCV entry factor functions in CHO and NIH3T3 cells. CHO cells expressing either of these human proteins in the context of the other three mouse proteins were slightly more permissive to HCVpp than cells expressing only the mouse proteins (Fig. 3b ). Furthermore, expression of both human CD81 and OCLN, together with murine SR-BI and CLDN1, rendered CHO cells as infectable with HCVpp as cells expressing all four human factors (Fig. 3b , compare last bar to any with human CD81 and OCLN). These results agree with our previous finding that mouse and hamster CD81, when expressed in the CD81deficient human hepatocellular carcinoma cell line HepG2, support only low level HCV entry (greater than tenfold reduced from human CD81) 14 . Importantly, these data indicate that CD81 and OCLN represent the minimal human-specific entry factors, at least in the context of mouse and hamster cells.
For CD81, the species-specific difference in HCV-entry activity between rat and human proteins maps exclusively to its large extracellular loop 14 . To determine the regions of OCLN that are responsible for the functional difference observed between mouse and human proteins, which are 91% identical, we expressed chimaeric OCLN molecules in 786-O cells and assayed HCVpp permissivity. In these experiments, a mouse chimaera bearing the second extracellular loop (EC2) of human OCLN was as active as the full-length human protein and at least fourfold more active than the mouse homologue (Fig. 3e,  compare mOCLN-hEC2 to hOCLN and mOCLN, respectively) . Conversely, a human OCLN mutant with the EC2 of the mouse protein functioned similarly to the full-length mouse factor in HCVpp infectivity (Fig. 3e, compare hOCLN-mEC2 to mOCLN) . These data suggest that the human-specific determinants of OCLN's HCV entry factor functions are entirely contained within EC2.
This study represents an important step forward in understanding both HCV host cell entry and HCV species tropism. All human, murine or hamster cell lines that we tested became permissive for HCV entry when engineered to express the molecules CD81, SR-BI, CLDN1 and OCLN. HCV entry into primary mouse hepatocytes might be complicated by the expression of additional dominant negative restriction factors absent in cell lines, which is experimentally difficult to address at this point. Our data suggest that OCLN completes the list of cell-type specific HCV entry factors; any other factors required for HCV entry must be ubiquitously expressed, or at least conserved between a wide range of human and mouse cells. The fact the OCLN is an important component of the tight junction complex further highlights the significance of this structure and cell polarity to HCV entry. We previously showed that CLDN1 acts late in the entry process, just before virion internalization 6 . The intimate association of CLDN1 and OCLN at the tight junction suggests that both these factors may function in a similar time frame. The use of several uptake factors with distinct cell surface distributions strengthens the hypothesis that HCV follows a coordinated entry pathway similar to that of coxsackievirus B. This virus initially interacts with a primary receptor (decay-accelerating factor) on the luminal cell surface, followed by lateral migration of the virus-receptor complex to the tight junction, where interaction with the coxsackievirus and adenovirus receptor is immediately followed by uptake into the host cell 15 . Notably, coxsackievirus B entry also requires OCLN 16 , further suggesting similar entry mechanisms of this virus and HCV. Recent work supports this stepwise model of HCV entry, demonstrating that initial engagement of CD81 on the cell surface, by either fluorescently labelled CD81 antibodies or soluble forms of the HCV glycoproteins, is followed by GTPase-dependent actin rearrangements that allow lateral movement of the CD81-bound complex into areas of cell-cell contact overlapping with both CLDN1 and OCLN localization 17 .
The study of HCV pathogenesis and the development of urgently needed effective antivirals and therapeutic and/or preventative vaccines targeting this virus have been severely hampered by the lack of convenient inbred small animal models capable of supporting HCV infection and replication. Numerous blocks will certainly need to be overcome before complete viral replication in a mouse can be achieved. HCV RNA replication in mouse cells is inefficient 1,2 , and the ability of such cells to support virion assembly is unknown. Our results clearly demonstrate, however, why mouse cells are unable to support HCV entry. This major block to HCV replication in murine cells can now be overcome simply by the expression of human CD81 and OCLN in the context of mouse CLDN1 and SR-BI, providing a clear foundation upon which a mouse model for HCV infection can begin to be constructed.
METHODS SUMMARY
For more detailed methods see Supplementary Methods. Pseudoparticles. Pseudoparticles were generated by FuGENE6 (Roche Applied Science)-mediated cotransfection of 293T cells with plasmids encoding (1) a minimal HIV (pTRIP, CSGW, CSPW) or MLV (LMN8) provirus encoding green fluorescent protein (GFP) or other transgene; (2) gag-pol (HIV or MLV); and (3) appropriate viral glycoproteins (HCV E1E2 or VSV-G). To generate Env 2 pp the glycoprotein vector was replaced with empty vector. Pseudoparticle-containing supernatants were collected at 24, 48 and 72 h, pooled and filtered (0.45 mm pore size). Pseudoparticle infections were performed in the presence of 4 mg ml 21 polybrene. A minimum of 72 h elapsed between transduction and reporter gene quantification by flow cytometry or subsequent experiments. Cyclic lentivirus cDNA library repackaging rescue screen. An Huh-7.5-derived cDNA library in the LMN8 retroviral vector (provided by P. Bieniasz) was packaged into VSVGpp and applied to NIH3T3 cells stably expressing human CD81, SR-BI and CLDN1 (N3xF26-NIH3T3 cells expressing 3 factors, FACS, clone 26), which were then challenged with HCVpp, encoding a puromycin (CSPW) resistance gene, and subjected to antibiotic selection ( Supplementary Fig. 1a ). Surviving clones were pooled and a fraction was tested for their susceptibility to GFP-encoding HCVpp. The populations were subsequently transfected with MLV gag-pol and VSV-G expression plasmids to package the LMN8 genomes with the cDNA inserts contained in the surviving N3xF26 cells into fresh VSVGpp (cyclic packaging rescue, CPR). These were used to transduce naive N3xF26 cells for subsequent rounds of screening (see Supplementary Methods for further details). Cell culture grown HCV. A plasmid encoding the chimaeric Jc1Flag2(p7-nsGluc2A) reporter genome 18 was XbaI linearized and transcribed using MEGAscript T7 (Ambion). RNA was electroporated into Huh-7.5 cells using an ECM 830 electroporator (BTX Genetronics) and HCVcc was collected from supernatants 48-72 h after transfection 19 .
